All In Biotech

NDA 020538 · Sandoz

Estradiol

Estradiol · Transdermal, Transdermal · Estrogen

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Jul 31, 1996

Approved uses

3

Original approval plus efficacy supplements

Registered trials

1,701

351 Phase 3, 176 recruiting

FAERS reports

49,280

23,503 serious, 922 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ENDOMETRIAL CANCER WITH UNOPPOSED ESTROGEN IN WOMEN WITH A UTERUS • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen-only therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. • Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in menopausal women with abnormal genital bleeding of unknown etiology [see Warnings and Precautions ( 5.2 )]. WARNING: ENDOMETRIAL CANCER WITH UNOPPOSED ESTROGEN IN WOMEN WITH A UTERUS See full prescribing information for complete boxed warning. There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens ( 5.2 )

What it is approved for

From the label in effect Oct 30, 2026.

VIVELLE-DOT is indicated for: VIVELLE-DOT is an estrogen indicated for: • Treatment of moderate to severe vasomotor symptoms due to menopause ( 1.1 ) • Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause ( 1.2 ) Limitations of Use When prescribing solely for the treatment of moderate to severe vaginal atrophy, first consider the use of topical vaginal products. • Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure ( 1.3 ) • Prevention of postmenopausal osteoporosis ( 1.4 ) Limitations of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. 1.1 Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause . 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy Due to Menopause Limitations of Use : When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, first consider the use of topical vaginal products. 1.3 Treatment of Hypoestrogenism Due to Hypogonadism, Castration, or Primary Ovarian Failure . 1.4 Prevention of Postmenopausal Osteoporosis Limitations of Use : When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis.

Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 3, 2002 Supplement 14 · Efficacy LetterLabel
  • May 3, 2002 Supplement 15 · Efficacy LabelReviewLetter
  • Jul 31, 1996 Original approval · Type 5 - New Formulation or New Manufacturer
9 products under this application
  • ESTRADIOL · ESTRADIOL 0.0375MG/24HR · Film, Extended Release, Transdermal · Discontinued
  • VIVELLE-DOT · ESTRADIOL 0.1MG/24HR · SYSTEM, TRANSDERMAL · Prescription · TE AB1
  • VIVELLE-DOT · ESTRADIOL 0.05MG/24HR · SYSTEM, TRANSDERMAL · Prescription · TE AB1
  • ESTRADIOL · ESTRADIOL 0.1MG/24HR · Film, Extended Release, Transdermal · Discontinued
  • ESTRADIOL · ESTRADIOL 0.075MG/24HR · Film, Extended Release, Transdermal · Discontinued
  • VIVELLE-DOT · ESTRADIOL 0.025MG/24HR · SYSTEM, TRANSDERMAL · Prescription · TE AB1
  • VIVELLE-DOT · ESTRADIOL 0.075MG/24HR · SYSTEM, TRANSDERMAL · Prescription · TE AB1
  • VIVELLE-DOT · ESTRADIOL 0.0375MG/24HR · SYSTEM, TRANSDERMAL · Prescription · TE AB1
  • ESTRADIOL · ESTRADIOL 0.05MG/24HR · Film, Extended Release, Transdermal · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.

All 1,701 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,108
  • headache3,056
  • nausea3,025
  • fatigue3,017
  • off label use2,458
  • pain2,204
  • diarrhoea2,023
  • dizziness1,839
  • product adhesion issue1,766
  • arthralgia1,724
  • breast cancer female1,724
  • rash1,640

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004543
2005601
2006444
20071,502
2008496
2009683
20101,067
2011964
20121,282
2013941
20141,165
20152,069
20162,638
20172,338
20182,607
20193,001
20203,034
20212,870
20223,164
20233,628
20243,783
20255,357
20265,102

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Estradiol* (Estradiol)

2024 spending

$218M

Beneficiaries

1,611,030

4,055,858 claims

Per beneficiary

$135

$1.69 per unit

View as table
YearSpending
2020$180,782,156
2021$216,405,766
2022$219,566,724
2023$239,028,017
2024$218,158,282

Part D: Vivelle-Dot (Estradiol)

2024 spending

$3.2M

Beneficiaries

2,792

10,989 claims

Per beneficiary

$1,151

$18.29 per unit

View as table
YearSpending
2020$5,023,634
2021$4,571,138
2022$4,153,664
2023$4,032,272
2024$3,213,854

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,473 on PubMed

Sponsor: Novartis · Also marketed as Vivelle-Dot

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.